Renovis, Inc. (Nasdaq: RNVS) announced that a pivotal Phase III study of NXY-059 (SAINT II) conducted by ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE